NEW YORK – Arbor Biotechnologies and Lonza said on Wednesday that they have forged a licensing agreement that will provide Lonza with access to Arbor's CRISPR-based gene editing technology.
Under the terms of the deal, Basel, Switzerland-based Lonza will be able to use Arbor's technology in its bioproduction products and services. Financial terms of the deal were not disclosed.